Skip to main content
. 2022 Jan 26;21:31. doi: 10.1186/s12943-022-01503-1

Table 1.

List of c-Met inhibitors

Drug Study Phase
Crizotinib (PF0234I066) NCT00585I95 I
Cabozantinib (XL184) NCT0I8664I0 II
NCT0I708954 II
NCT00940225 II
Foretinib (GSKI363089) NCT0I068587 I/II
Tepotinib (EMDI2I4063) NCT02864992 II
Rilotumumab (AMG102) NCT02137343 III
Ficlatuzumab NCT03422536 II
Tivantinib (ARQ197) NCT01244191 III
Capmatinib (INC280, INCB28060) NCT0I324479 I
NCT0I60336 II